Background: miRNA is a key component of post-transcriptional network governing the fate of T cells. Results: By targeting PTEN and IKZF4, miR-17-92 cluster promotes T H 17 differentiation and T H 17-related inflammation. Conclusion: miR-19b and miR-17 within the cluster additively promote T H 17 responses through distinct regulatory networks. Significance: Our study provides novel regulatory mechanisms and potential therapeutic candidates against autoimmunity.
MicroRNAs (miRNAs)
2 are a class of small non-coding RNAs with versatile regulatory functions in eukaryotic cells. Mature miRNAs are mounted onto the RNA-induced silencing complex which interacts with a particular mRNA molecule. This process leads to translational repression and/or RNA decay of target mRNA (1) . Dysregulated miRNA expression has been associated with a variety of immunological diseases (2) , depicting miRNA's indispensable role in maintaining proper immune defense and immune homeostasis (3) (4) (5) .
As a critical compartment of the adaptive immune system, CD4
ϩ T cells are well recognized by their capability of differentiating into various T cell subtypes to accomplish different tasks: T H 1 cells secrete IFN␥ and are involved in anti-viral and anti-tumor immunity; T H 2 cells produce IL-4, IL-5, and IL-13 to defend against helminth infection; T H 17 cells can produce IL-17, IL-22, and IL-23 and controls fungi invasion; T follicular helper cells (T FH ) supports B cell affinity maturation to elicit proper humoral immunity; Tregs, on the other hand, downscale immune responses to prevent excessive inflammation (6) .
Among the numerous immunoregulatory miRNA species, the miR-17-92 cluster had been suggested to play pivotal roles in the regulation of immune responses, including CD4 ϩ T cell differentiation. MiR-17-92 was the first "oncomiR" ever identified: its expression was highly elevated in lymphoma B cell from cancer patients and its overexpression accelerated tumorigenesis (7); on the other hand, in the immune system, our group demonstrated that miR-17-92 is indispensable for anti-tumor CD4 ϩ T cell responses by enhancing IFN␥-secreting T H 1 differentiation and by supporting tumor-specific T cell survival and proliferation (8) . These pro-inflammatory functions of this unique cluster were complemented by recent reports that miR-17-92 is essential for eliciting optimal antibody responses by affecting T FH differentiation (9, 10) . Moreover, miR-17-92 also carries a mechanism that biases CD4 ϩ T cells away from immune tolerant T reg induction. In the absence of miR-17-92, CD4 ϩ T cells were poised for strong iTreg differentiation (8) ; and, thymic-derived Tregs critically rely on miR-17-92 for their IL-10 production and immune suppressive functions (11) .
Although miR-17-92's regulatory functions have been elaborated in a variety of immunological responses, its effect in autoimmunity was not well established. Some evidence suggests this cluster may be involved in multiple sclerosis (MS), as one member of miR-17-92, miR-17 was shown to be up-regulated in MS patients (12) . MS is an autoimmunity-mediated neuro-demyelination disease elicited by the activation of T H 17 cells. Besides its pivotal role in anti-fungal responses, T H 17 is also a pathogenic branch of CD4 ϩ T cells contributing to the onset of various autoimmune diseases, including MS (13) (14) (15) . In MS patients, myelin specific T H 17 cells infiltrate into the central nervous system (CNS) and produce pro-inflammatory cytokines such as GM-CSF and IL-17 (16, 17) . IL-17 secreted from T H 17 cells can stimulate astrocytes and attract neutrophils to foster the inflammation (18) . IL-17 was also shown to directly target glial cells, which potentially impedes myelin repair and aggravates disease progression (19) . Because of the importance of T H 17-mediated pathogenesis in MS, key regulators of T H 17 differentiation have been extensively studied (20, 21) . Transcriptional network mapping has uncovered the key modulators of T H 17 lineage initiation, commitment and stabilization (22, 23) . However, since the role of miR-17-92 in T H 17 lineage is yet to be investigated, it is unclear whether this transcription factor network relates to the post-transcriptional regulatory network of miR-17-92.
In this study, we utilized a mouse strain in which miR-17-92 was specifically depleted in T cells. In combination with the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, we showed that loss of miR-17-92 resulted in impaired T H 17 differentiation, which consequently reduced EAE pathogenesis. We further dissected this cluster and identified specific miRNAs executing the whole cluster's function. Through identification of their functionally relevant gene targets, we elucidated the molecular mechanism underlying these regulatory miRNAs.
EXPERIMENTAL PROCEDURES

Animals-miR-17-92
f/f and Rag2 Ϫ/Ϫ mice were purchased from the Jackson Laboratory. CD4-Cre mice were purchased from Taconic. CD4 ϩ T cell conditional miR-17-92 knock-out mice were generated by mating miR- f/f and CD4-Cre mice and back-crossing to the C57BL/6 background. All animal-related procedures were conducted with the approval from the Duke University Animal Care and Use Committee.
In Vitro Cell Culture, T H 17 Polarization and Retrovirus Infection-For in vitro cultures, total lymph nodes or spleen were collected from mice and single cell suspension was prepared. CD4 ϩ Cells were then purified with Dynabeads Untouched TM Mouse CD4 Cells kit (Invitrogen). Cells were stimulated by 1 g/ml plate-bond ␣-CD3 and ␣-CD28antibodies. 10 g/ml ␣-IFN␥, 10 g/ml ␣-IL-4, 50 ng/ml mouse IL-6, 4 ng/ml human TGF␤, 20 ng/ml mouse IL-1␤, and 50 ng/ml IL-23 were added in the culture for T H 17 polarization. Antibodies described above were purchased from BioXCell, and cytokines from Biolegend. PIK-75 (PI3K inhibitor) was purchased from EMD Biosciences (#528116) and was applied at the concentration of 25 nM. miRNA overexpression vectors were constructed with MSCV retrovirus backbone, and retroviruses were generated by transfecting the BOSC 23 packaging cell line. Viruses were harvested from the supernatant 48 h post-transfection. Retroviruses were then used to infect activated T cells by centrifugation at 1258 ϫ g at 37°C.
RT-qPCR, Luciferase Assay and Western Blot-RNA was extracted from cells by mirVana TM miRNA Isolation kit (Invitrogen). Reverse transcription was performed using qScript TM Flex cDNA kit (Quanta Biosciences). Quantitative PCR was conducted with PerfeCTa SYBR Green FastMix (Quanta). 96-well qPCR array primers were synthesized from Integrated DNA Technologies. miRNA-target binding was predicted using online algorithm TargetScan. Luciferase reporter vector was constructed by cloning target 3Ј-UTR downstream of firefly luciferase. This vector also contains Renilla luciferase transcribed from a separate promoter. By normalizing firefly luciferase to Renilla luciferase, the repression efficacy of miRNA was assessed. Western blot was performed using Novex 10% Tris-Glycin Gel (Invitrogen). Primary antibody ␣-IKZF4 was acquired from Santa Cruz Biotechnology (sc-292209), ␣-Actin␤ from Sigma-Aldrich. Secondary antibody ␣-rabbit-Alexa Fluor 680 was purchased from Invitrogen.
Flow Cytometry-Flow cytometry antibodies were purchased from Biologend. For surface staining, the cells were harvested and stained in FACS buffer (PBS with 2% FBS and 2 mM EDTA). For intracellular cytokine staining, the cells were harvested and further stimulated with 500 ng/ml Ionomycin and 1 M PdBU (Sigma Aldrich) in the presence of Golgi block Monensin and Brefeldin A (eBioscience) for 4 h, followed by fixation in 2% paraformaldehyde-PBS and permeabilization in 0.1% Saponin-FACS buffer. For Foxp3 stanining, cells were processed and stained with Foxp3 staining buffer kit (eBioscience). For intracellular IKZF4 staining, the cells were first fixed in 2% paraformaldehyde-PBS and permeabilized in 90% methanol-PBS. Subsequently, cells were subjected to primary rabbit-␣-mouse IKZF4 (Santa Cruz Biotechnology) and secondary antibody staining (Jackson Immunoresearch). Flow cytometry was conducted with BD FACSCanto TM II analyzer. Experimental Autoimmune Encephalomyelitis Induction-125 g of myelin oligodendrocyte glycoprotein (MOG) peptide was emulsified in complete freund's adjuvant (CFA). The mix was injected into the mouse subcutaneously. 200 ng/mouse of pertussis toxin was injected intravenously on day 0 and day 2 postimmunization. Clinical score was assessed on a daily basis according to the extent of paralysis: no clinical symptoms (0); limp tail (1); weak paralysis of two hind limbs (2); complete paralysis of two hind limbs (3); paralysis of both hind and fore limbs (4); death (5) .
Hi naïve T cells were sorted from donor mice and 0.5 million cells were injected into recipient mice intraperitoneally. Mouse body weights were monitored on a daily basis. At the experiment end-point, mice were sacrificed and the colon weight/length ratios were measured. Mesenteric lymph nodes and spleens were collected, and T cells were analyzed for intracellular expression of IL-17A and IFN␥ expression by flow cytometry.
Statistics-Two-tailed Student's t tests were used to determine whether the means from two experimental groups were significantly different. p values of Ͻ0.05 was indicative of significant difference. In certain time-course studies, the difference between two groups were accessed via testing whether the regression slope were significantly different. p value of Ͻ0.05 indicates the samples of interest do not derive from a single population.
RESULTS
miR-17-92 Deficiency in CD4 ϩ T Cells Leads to Impaired T H 17 Differentiation in Vitro and Mitigates EAE Progression-
To investigate the role of miR-17-92 cluster in the differentia-tion of T H 17 cells, we employed the miR-17-92 f/f -CD4-Cre conditional knock-out mouse as previously described (8) . This mouse line features two loxp sites flanking the whole miRNA cluster (24) , together with Cre expression under the control of CD4 promoter to ensure T cell-specific miR-17-92 depletion. With these mice, we first tested whether miR-17-92 cluster affects T H 17 differentiation in vitro. Using plate-bound anti-CD3 and anti-CD28 antibodies, CD4 ϩ T cells from total lymph nodes of either wild type (WT), miR-17-92 heterozygotes (f/ϩ) or miR-17-92 knock-out (f/f) mouse were stimulated through their antigen receptors. The cells were cultured under T H 17 polarization conditions to assess their differentiation capacity. T H 17 differentiation of miR-17-92-deficient T cells was markedly decreased in vitro, as identified by reduced IL-17A production (Fig. 1A) .
We next studied the impact of this impaired T H 17 differentiation in vivo using the EAE mouse model of MS. Since T H 17 cells are known to be the critical mediators of MS in human patients, we induced EAE in either wild-type (WT) mice or miR-17-92 f/f -CD4-Cre (KO) mice. In KO mice, we observed alleviation in EAE symptoms, as indicated by reduced clinical scores (Fig. 1B) . We found no significant differences in the numbers of pathological CD4 ϩ T cells infiltrating the central nervous system (Fig. 1C ). However, a closer examination at the effector function of these CD4 ϩ T cells revealed that KO cells collected from the spinal cords and spleens of EAE mice had significantly diminished IL-17 expression (Fig. 1, D and E) , together, the IL-17 producing cell number was also significantly decreased (supplemental Fig. S1 ). Consistent with our previous findings that miR-17-92 facilitates IFN␥ production (8), we also observed a significant decrease in IFN␥ producing T cells in the spinal cord. However, although the loss of miR-17-92 enhanced iT reg induction in vitro and within the tumor microenvironment (8), under our EAE inducing condition, we were unable to identify differences in Treg percentages between WT and KO mice, in both the spinal cords and spleens (Fig. 1F) f/ϩ -CD4-Cre (f/ϩ), or miR-17-92 f/f -CD4-Cre mice (f/f) mice and stimulated by anti-CD3⑀ and anti-CD28 for 5 days in T H 17 skewing conditions, followed by intracellular staining for IL-17A and IFN␥ and flow cytometry analysis. B, wild type (WT, n ϭ 10) and miR- f/f -CD4-Cre (KO, n ϭ 5) mice were immunized with MOG peptide and injected with pertussis toxin to elicit EAE, and the clinical score is measured daily according to "Experimental Procedures." C-F, cells from EAE day 26 mice were collected from spinal cord (SC), spleen (SPL), and lymph nodes (LN) and analyzed for T cell number (C), IL-17A, IFN␥ expression (D, E), and Foxp3 expression (F). Statistics were done by unpaired Student's t test with error bars indicating S.E.
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mouse, the adoptively transferred naïve CD4 ϩ T cells become activated and differentiate into T H 1 and T H 17 lineages to induce colitis (25) . We adoptively transferred CD4
Hi naïve WT or KO T cells into the Rag2 Ϫ/Ϫ hosts, and monitored their body weights daily. Compared with WT T cells, we found that KO T cells were ineffectual at eliciting colitis-induced weight loss: in recipients of KO T cells, weight loss was significantly retarded (Fig.  2A) . In addition, the colon weight/length ratio, an indicator of colon inflammation severity, was significantly reduced in mice receiving KO T cells (Fig. 2B) . Accordingly, H&E staining of the colon sections revealed stark differences between the two groups of recipient mice: in the colons of mice receiving WT T cells, there was drastic loss of villus integrity, together with substantial infiltration of inflammatory mononuclear cells into the villi, and, severe depletion of goblet cells; In the colons of mice receiving KO T cells, while mononuclear infiltration was present, the gross architecture of both villi and goblet cells remained intact (Fig. 2C) . Further analysis revealed that miR-17-92 deletion results in significantly reduced accumulation of CD4 ϩ cells in the mesenteric lymph nodes (Fig. 2D) , which is likely a consequence of reduced proliferation and increased activation-induced apoptosis associated with miR-17-92 deletion (8) . More importantly, while IFN␥ production was comparable between two groups in this disease model (Fig. 2E) , we observed suppressed IL-17A expression in transferred KO T cells (Fig. 2F) . Notably, in our colitis model, iTreg differentiation was negligible in either WT or KO CD4 ϩ T cell transfer (supplemental Fig. S2 
CD45RB
Hi naïve T cells were sorted from wild type (WT) and or miR-17-92 f/f -CD4-Cre mice (KO) mice and adoptively transferred into Rag2 Ϫ/Ϫ recipients. Body weights of WT and KO recipients were measured daily after T cell transfer, and were normalized to the initial body weight of each mouse. The left and right panels represent two independent experiments. B, colons were harvested from mice 11 days post WT or KO T cell transfer, and colon weight/length ratio (an indicator of colitis severity) was calculated. C, H&E staining of the colon sections of mice with WT or KO T cell transfer. Note the differences between the two groups, in terms of mononuclear cell infiltration (density of blue staining), numbers of goblet cells (cells with white vacuoles) and villus integrity. D-F, quantification of absolute CD4 ϩ T cell numbers, IFN␥ ϩ and IL-17A ϩ T cell percentages and cell numbers in the mesenteric lymph nodes of WT and KO groups. Statistics were calculated by unpaired Student's t test; error bars indicates S.E. Specifically, the p value of right panel in A was determined by testing whether there is a significant difference between the regression slopes of WT and KO group.
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MAY 2, 2014 • VOLUME 289 • NUMBER 18 miRNAs in this cluster. By utilizing retroviral vectors to overexpress individual miRNAs in miR-17-92 knock-out T cells, we were able to achieve miRNA expression above the wild type level (supplemental Fig. S3 ). We then found that two miRNAs, miR-17 and miR-19b, were most potent in rescuing the T H 17 differentiation defect (Fig. 3, A and B) . We then asked if miR-17 and miR-19b promotes T H 17 differentiation in an additive or synergistic manner. To examine their combinatory effects, we designed a retroviral vector that expresses a miR-17-92 mutant, miR-1719b. miR-1719b harbors deletions of the miR-19a and miR-20a guide strands, and contains mutations covering the whole seed regions of miR-18 and miR-92. This allows us to overexpress miR-17 and miR-19b simultaneously in the context of their original cluster (Fig. 3C) . Combined miR-17 and miR-19b expression demonstrated an additive effect in driving T H 17 differentiation of KO CD4 ϩ T cells in comparison to those cells expressing miR-17 or miR-19b alone (Fig. 3D) . Accordingly, the transcription of il17a, il17f, and master regulator rorc were also highly induced by concurrent expression of miR-17 and miR-19b (Fig. 3D) . Collectively, by breaking down the miR-17-92 cluster into individual miRNAs, we demonstrated that miR-17 and miR-19b are potentially the major players in promoting T H 17 differentiation.
miR-19b Enhances T H 17 Differentiation by Targeting PTENWe then examined how miR-19b functions to foster T H 17 differentiation. We and others have validated phosphatase and tensin homology (PTEN) as a target of miR-19b in tumor cells, B cells, and CD4
ϩ T cells (8, 26) . By dephosphorylating PIP 3 , PTEN is well recognized as a negative regulator of the PI3K-AKT-mTOR signaling pathway (27) . Importantly, recent studies imply that activation of the PI3K-AKT-mTOR pathway is essential for the induction of T H 17 differentiation in vitro and in vivo (28) . Therefore, we speculated that miR-19b promotes T H 17 response through the inhibition of PTEN to enhance the PI3K-AKT-mTOR pathway. We first confirmed that miR-19b overexpression is capable of down-regulating PTEN during the differentiation of T H 17 cells (Fig. 4A) . One direct consequence of PTEN dysregulation is the alteration of AKT activation, marked by the phosphorylation of two critical residues on AKT: threonine 308 (T308) and serine 473 (S473) (29) . When we activated WT and KO CD4 ϩ T cells via TCR stimulation under the T H 17-differentiating conditions, we observed that both T308 and S473 phosphorylation were significantly retarded in KO cells (Fig. 4B) . We then examined whether this miR-19b-mediated PTEN down-regulation is sufficient to influence T H 17 differentiation. With a low dose of the selective inhibitor PIK-75, we specifically blocked the activity of p110␣ subunit of PI 3 kinase to assess the contribution of the PI3K-AKT-mTOR pathway for T H 17 differentiation in miR-17-92 KO CD4 ϩ T cells (30) . We reasoned that the loss of miR-19b should already have accumulated sufficient PTEN in these KO cells to increase the PI3K-AKT-mTOR signaling threshold required for T H 17 differentiation. Therefore, KO cells would be less susceptible to further pharmaceutical inhibition of PI3K. By differentiating CD4 T cells in vitro in the presence or absence of PIK-75, we could determine the inhibition index of T H 17 differentiation (1-IL-17 PIK-75 /IL-17 DMSO ). While PIK-75 is still capable of reducing IL-17 production in KO CD4 ϩ T cells (Fig. 4, C and   D) , the extent of reduction is significantly lower in these miR-17-92-deficient T cells (Fig. 4E ). In addition, in the absence of PI3K inhibition, both miR-17 and miR-19b rescued KO cells' defect in Th17 differentiation (Fig. 4, C and D) . However, in the presence of PI3K inhibition, the rescue by miR-17 and miR-19b differs significantly: rescue delivered by miR-19b depends on PI3K activation (Fig. 4, C and D) and is highly sensitive to PIK-75 treatment; rescue delivered by miR-17, which functions through a PTEN-independent mechanism (Fig. 4A) , is more resistant to PI3K inhibition (Fig. 4E) . Taken together, we concluded that miR-19b enhances T H 17 differentiation by targeting PTEN.
miR-17 Promotes T H 17 Differentiation by Repressing Novel Target IKZF4-Previously, we identified that miR-17 protects CD4
ϩ T cells from excessive activation induced cell death and inhibits iTreg differentiation by targeting the upstream signaling molecule TGFBRII and the transcription factor CREB1 (8).
Although they are implicated in T cell differentiation (31-33), we failed to detect any significant change in the expression of these two proteins in T H 17-biased CD4 ϩ T cells (supplemental Fig. S4 ). To identify the direct target(s) of miR-17 during T H 17 differentiation, we conducted a qPCR array on 93 core mediators controlling various stages of T H 17 differentiation. These genes were selected based on recent transcription factor network analysis of differentiated T H 17 cells and dynamic regulatory network analysis of T H 17 cells during the differentiation process (22, 23) . Our list of core mediators (supplemental Table  S1 ) includes validated T H 17 regulators (ROR␥t, STAT3, BATF, etc.) as well as new and predicted key modulators (MINA, FOSL2, SP1, etc.). We collected RNA samples from WT and KO cells transduced with control, miR-17 or miR-19b vectors and performed 5 rounds of qPCR array (Fig. 5A , data as in supplemental Table S1 ). Among the significantly changed genes, we focused on genes that are up-regulated in miR-17-deficient KO CD4 ϩ T cells, and, down-regulated when miR-17 was re-introduced (Fig. 5A ). With these filtering criteria, we identified two genes, EBI3 and IKZF4, which fit this pattern and are also known to be negative regulators in T H 17 differentiation. IKZF4 belongs to the Ikaros zinc finger transcription factor family and was recently shown to be a composite of the negative module in T H 17 differentiation network (23) . With computational algorisms, we failed to identify any conserved miR-17 binding sites in EBI3 mRNA; but, we predicted two potential miR-17 binding sites in the 3Ј-untranslated region (3Ј-UTR) of murine IKZF4 (Fig. 5B) , with position 2394 being highly conserved among mammals. We cloned the IKZF4 3Ј-UTR containing these two miR-17 binding sites into a luciferase reporters and transfected the construct into 3T3 cells stably transduced with control or miR-17 retrovirus. As expected, miR-17 significantly repressed the expression of IKZF4 3Ј-UTR conjugated reporter (Fig. 5C ). Importantly, during T H 17 differentiation, protein levels of IKZF4 was also increased in the KO cells but reduced when miR-17 was reintroduced (Fig. 5D) . Therefore, we concluded that IKZF4 is a direct target of miR-17.
To further validate whether miR-17-mediated IKZF4 suppression directly promotes T H 17 differentiation, we constructed a rescue vector with concomitant expression of miR-17-92 Cluster Targets PTEN and IKZF4 to Promote T H 17 Responses miR-17 and the IKZF4 coding sequence concordantly. We found that while miR-17 increases T H 17 differentiation in WT cells, this increase is significantly tuned down when exogenous IKZF4, which can bypass miR-17 targeting, was introduced (Fig. 5E) . Therefore, we concluded that transcription suppressor IKZF4 is a novel target of miR-17, and this targeting is crucial for miR-17's effect in promoting T H 17 differentiation. 
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DISCUSSION
In this study, we demonstrated miR-17-92 cluster as a novel regulator of T H 17 differentiation and its effector pathogenicity. In combination with our previous data that miR-17-92 facilitates cell proliferation, inhibits apoptosis, promotes T H 1 differentiation, and impairs iTreg differentiation, our findings accentuate the notion that this cluster comprehensively controls inflammation elicited by antigen-specific CD4 ϩ T cell activa- 
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tion. Evolutionarily, miR-17-92 is highly conserved in mammals (34) , and by promoting CD4 ϩ T cell mediated immunity, this cluster may confer survival benefits against non-self intrusions. However, overactivation of T cells also leads to severe consequences such as autoimmune diseases (35, 36) . Our animal models indicate this miRNA cluster may be involved in the pathogenesis of MS in humans. By dissecting the individual miRNAs in the context of T H 17 differentiation, we revealed different behaviors of the miRNAs in the cluster, with miR-17 and miR-19b exerting the most potential in driving T H 17 differentiation and may contribute mostly to the onset of MS. This finding also suggests that MS therapies can be designed by targeting miRNAs. The safety and efficacy of oligonucleotide therapy against miRNAs have not only been tested in primates, but have also passed phase 2 human trials (36) . Since miR-19b was also found to promote T H 1-mediated inflammation (8) , and oligonucleotides against miR-19b may not only benefit MS patients, but also a wide array of inflammatory diseases.
The finding that miR-19b affects PI3K-AKT-mTOR axis in T H 17 differentiation is well consistent with our previous report, in which miR-19b represses PTEN to facilitate CD4 ϩ T cell's anti-tumor response (8) . Indeed, PI3K-AKT-mTOR is a central regulatory axis in T H 17 differentiation: the activation of this pathway phosphorylates STAT3 and enhances the transcription of ROR␥t, the master transcription factor for T H 17 lineage (37); moreover, PI3K-AKT-mTOR was found to facilitate ROR␥t nuclear translocation, while suppressing the T H 17-negative regulator GFI1 (38) . Additionally, PI3K-AKT-mTOR activation is also indispensable for efficient T H 1 differentiation (37) . As an antagonist of the PI3K-AKT-mTOR axis, PTEN acts as an important anti-inflammatory mediator by reducing both T H 1 and T H 17 mediated pathogenesis. Therefore, by repressing PTEN in T cells, miR-19b is able to extensively drive immune activation and inflammation.
We previously demonstrated that miR-17 can inhibit iTreg differentiation by targeting TGFBRII (8) , and the dominant negative form of TGFBRII was found to impede T H 17 differentiation (31) . In view of this, there is a seemingly inverse correlation between miR-17 expression and the T H 17 pathway. However, in our study, we did not detect changes of TGFBRII when miR-17 is overexpressed in T H 17 cells (supplemental Fig.  S4 ). This is probably due to differences in miR-17 targeting between the T H 17 and iTreg contexts.
Instead, we identified IKZF4 as a target of miR-17 in controlling T H 17 differentiation. IKZF4 is a member of the Ikaros family transcription factors. The Ikaros family was originally designated to function in hematopoiesis (39) , but it is only until recently that studies begin to show the relevance of this family in T helper cell differentiation. IKZF3 was preferentially expressed in T H 17 cells and governs T H 17 differentiation by silencing IL-2 expression (40) . By investigating the dynamics of the T H 17 regulatory network, IKZF4 was proposed by Yosef et al. as a composite in the negative regulatory module for T H 17. However, the function of this protein remained elusive. In our report, we provide the first evidence that miR-17 reinforces T H 17 differentiation by repressing IKZF4.
T H 17 and iTreg differentiation processes are mutually antagonistic; however, the plasticities of both lineages remain preserved in differentiated cells (41, 42) . Although cytokine signaling plays vital roles in directing the T H 17 and iTreg differentiation paradigms (43) , a more fundamental diversion should occur at the epigenetic level. Pan et al. demonstrated that IKZF4 has the potential to function at the epigenetic level. By recruiting CtBP1 to epigenetically silence IL-2 and IFN␥, IKZF4 reinforces the suppressive functionality of thymic-derived nTregs (44) . In addition, Munn et al. demonstrated that IKZF4 is critical for maintaining the lineage specificity of nTregs (45) . We speculate that a similar mechanism could be at play during iTreg differentiation, and, IKZF4 may function as an intrinsic modulator in T cells that decides between the T H 17 and iTreg lineage choices. This lineage choice is also impacted by miR-17: miR-17 biases T cells toward the T H 17 lineage, while inhibiting iTreg differentiation (8) . Therefore, we propose that by modulating IKZF4 expression, miR-17 is a posttranscriptional mechanism controlling T H 17/iTreg plasticity.
Our molecular dissection indicated that miR-17 and miR19b are united in many ways to promote the effector function of CD4 ϩ T cells: protecting cells from activation-induced death, inhibiting iTreg differentiation, and, supporting T H 17 differentiation. It is tempting to speculate that signaling pathways modulated by miR-17 and miR-19b may cross-talk with each other. Intriguingly, it has been shown that, in pro-B cells, the activation of PI3K is essential in controlling IKZF1 expression and therefore successful VDJ recombination (46) . However, under both T H 1 and T H 17 conditions, manipulation of miR-17 did not cause any measurable impact on PTEN expression (Fig. 4) ; manipulation of miR-19b could not alter CREB1, TGFBRII (8), or IKZF4 expression (supplemental Fig. S5 ). Therefore, we concluded that miR-17 and miR-19b most likely modulate two independent signaling networks and their effects on CD4 ϩ T cells are additive.
Recently, other groups reported that miR-17-92 promotes T FH differentiation by repressing genes involved in T H 17 differentiation (9) . However, it should be noted that, in this study, the experimental setup does not recapitulate the physiological conditions required for optimal T H 17 induction: LCMV-specific CD4 ϩ T cells carrying miR-17-92 deficiency were transferred into recipient mice followed by LCMV inoculation. In fact, LCMV infection elicits robust T H 1, rather than T H 17 responses. Under these circumstances, the T FH population generated might possess characteristics of T H 1 cells (47), which could fundamentally differ from the bona fide T H 17 cells generated in the EAE model. Given the context-dependent nature of miRNA targeting, they do not necessarily contradict miR-17-92's positive effect in T H 17 differentiation in the EAE and colitis settings. Interestingly, RORA was reported to be a target of miR-17-92 in their particular system, and we also detected an increase in RORA at the transcription level in miR-17-92-deficient cells by our qPCR array (Fig. 5A) 
